We believe that in the future, software applications will become an integral part of treatments offered by Pharma companies in the form of Hybrid Drugs™. These will include both a software component and a traditional drug component - influencing patients via Hybrid Mechanisms of Action™. Remepy’s Digital Molecules™ are designed to be the software components within Hybrid Drugs™. They are based on digital interventions and treatment protocols that are tailored to each medical condition and its corresponding drug.

Remepy (רמפי בריאות בע)

Remepy (רמפי בריאות בע)